Clinical Trial Update: Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of an anti-CD137 antibody with ipilimumab in melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• anti-CD137 antibody
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 1 | Status: WITHDRAWN